CAS
INFI

CTC Alternative Strategies’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

CTC Alternative Strategies’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-10,900
Closed -$151K – 221
2013
Q4 		$151K Buy
+10,900
New +$154K 0.11% 98

Other funds holding INFI

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CTC Alternative Strategies's INFI Position: Q1 2014 in Review

CTC Alternative Strategies sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2014, closing a stake of 10,900 shares — an estimated $151K sold.

CTC Alternative Strategies first reported a position in INFI in Q4 2013 and held it in 1 quarter. The position peaked at $151K in Q4 2013. 98 funds tracked by Wall St. Rank hold INFI as of Q1 2014.

  • CTC Alternative Strategies reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2014 after selling out during the quarter.
  • CTC Alternative Strategies sold 10,900 Infinity Pharmaceuticals, Inc. shares in Q1 2014, an estimated $151K.
  • CTC Alternative Strategies first reported a position in Infinity Pharmaceuticals, Inc. in Q4 2013 and held it in 1 quarter.
  • CTC Alternative Strategies's Infinity Pharmaceuticals, Inc. position peaked at $151K in Q4 2013.
  • 98 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2014.

Based on CTC Alternative Strategies's 13F filing for Q1 2014, filed 2 May 2014.